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Genital herpes simplex virus type 2 (HSV2) is highly prevalent
worldwide and an increasingly important cause of genital ulcer
disease (GUD). Continued HSV2 transmission is facilitated by
the large number of undiagnosed cases, the frequency of
atypical disease and the occurrence of asymptomatic shedding.
The lack of easy, affordable diagnostic methods and specific
antiviral treatment in countries with low and middle income is of
great concern, given the ability of GUD to enhance HIV
transmission and acquisition. With rising HSV2 prevalence
contributing to an increase in the proportion of GUD attributed
to genital herpes in high-HIV prevalence settings, a safe and
effective HSV vaccine is urgently needed. Meanwhile,
multifaceted interventions are required to improve recognition
of genital herpes, to prevent its spread and also to prevent its
potential to promote HIV transmission in developing countries.
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G
enital herpes infection is the primary cause
of genital ulcer disease (GUD) worldwide.1
It is mainly caused by herpes virus simplex
(HSV) type 2 (HSV2) but can also be caused by
HSV1. HSV1 has been estimated to cause 30% of
cases of primary genital herpes in the US.2 In
developing countries, the proportion of genital
herpes caused by HSV1 is unknown, although it is
assumed to be low. Recent attention has focused
on the role of HSV2 as a cofactor for HIV infection
and, hence, HSV2 treatment may have a role as an
HIV prevention strategy. The World Health
Organization (WHO) has recently issued new
guidelines for the syndromic management of
genital ulcers, which recommend antiviral treat-
ment for herpes in settings with high HSV2
prevalence.3 Aciclovir is inexpensive, well tolerated
and has an acceptable profile for widespread
treatment; however, it is not widely available in
countries with low and middle income. While an
effective HSV vaccine is available, other treatment
and control strategies need to be evaluated and, if
effective, implemented.
This paper reviews the epidemiology of HSV2 in
developing countries, the importance of HSV2 as a
cause of GUD, the available evidence on the
interaction between HSV2 and HIV, the diagnostic
options in developing countries and the role of
antiherpes treatment in the management of GUD.
SEARCH METHODS
To identify relevant published literature, we com-
prehensively searched the Medline database cover-
ing studies from 1985 to 2005. The websites of the
WHO, US Centers for Disease Control and
Prevention, UK Public Health Laboratory Service
and UK Medical Society for the Study of Venereal
Diseases were also searched for relevant publica-
tions and abstracts. Search terms used were ‘‘genital
herpes’’, ‘‘STI (sexually transmitted infection)’’ and
‘‘developing countries, genital ulcer, HSV, HSV-2,
herpes’’. For the review of GUD aetiology in
developing countries, we included all papers that
reported laboratory methods used, and we excluded
those that provided only clinical diagnosis.
HSV2 EPIDEMIOLOGY
Few countries have population-based national
estimates of HSV2 that allow the estimation of
seroprevalence trends. In the US, a representative
national sample of the population aged >12 years
indicated that age-adjusted HSV2 prevalence has
increased from 16.4% to 21.7% of adults from 1976
to 1994.4 European cross-sectional surveys con-
ducted between 1989 and 2000 found that age-
standardised HSV2 seroprevalence ranged from 4%
in England and Wales to 24% in Bulgaria.5
Compared with developing countries, substan-
tially higher rates of HSV2 have been observed in
sub-Saharan Africa, with age-adjusted prevalences
in adults ranging from 30% to 80% in women and
10% to 50% in men (fig 1). In South America,
available data are mainly for women, in whom
HSV2 prevalence ranges from 20% to 40%.
Prevalence in the general population in Asian
countries shows lower values, from 10% to 30%.6
The changing epidemiology of GUD
The prevalence and aetiology of GUD in different
geographical regions and populations in Africa seem
to vary widely, and are also changing over time.
Studies on GUD in developing countries published
before 1995 identified syphilis and chancroid as the
main causes of GUD (table 1).7–35 In resource-poor
nations, the spread of HIV and factors such as
enhanced case identification and treatment for
bacterial GUD since 1990 seem to have resulted in
altered epidemic patterns of sexually transmitted
infections (STIs). Among studies conducted during
the past 10 years, HSV2 has been reported as an
important cause of GUD in Africa, South East Asia
and Latin America. In at least seven locations in
Africa where longitudinal data are available, there is
evidence of a shift in the aetiology of GUD towards
HSV2 (table 1). For example, cross-sectional studies
among miners in South Africa reported that the
Abbreviations: GUD, genital ulcer disease; HSV, herpes
simplex virus; PCR, polymerase chain reaction; STI, sexually
transmitted infection; WHO, World Health Organization
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proportion of ulcers due to herpes increased from 3% in 1986 to
17% in 1994 and to 36% in 1998.19 20 Paz-Bailey et al7 reported
similar findings from Botswana, where 24% of GUD among
patients with STIs was due to HSV2 in 1993, increasing to 60% in
2002. In Botswana, the increases in HSV2 were still marked after
adjusting the prevalence for the differences in sensitivity and
specificity of diagnostic tests used in 1993 and 2002.
Possible explanations for the changes in GUD aetiology include
changes in laboratory techniques, HIV-attributable mortality
among high-risk groups, behavioural change, improved syndro-
mic management and increase in antibiotic use. Changes in
laboratory techniques, including availability of more sensitive
tests such as polymerase chain reaction (PCR), may explain some
of the differences but cannot account for all the observed changes
in prevalence.7 HIV-attributable mortality might disproportio-
nately affect the prevalence of chancroid, which heavily relies on
core groups to persist. In contrast, owing to its longer duration of
infection, HSV2 does not rely on people at high risk to spread and
is less influenced by the differential mortality associated with
AIDS.36 37 Syndromic management was implemented in several
countries in Africa in the early 1990s, and widespread use of
antibiotics, together with mandatory serological testing for
syphilis, may have contributed to a decrease in the prevalence
of syphilis and other STIs.
HSV2 AND HIV
An increasing body of literature suggests that HIV and HSV2
manifest bidirectional interactions. Clinical, biological and
epidemiological studies support the hypothesis that HSV2
increases the efficiency of HIV acquisition38–43 and transmis-
sion.30 44–46 Similarly, HIV may increase susceptibility to HSV2,
HSV2 shedding47–49 and, at low CD4 counts, severity of clinical
manifestations.50
In terms of HIV acquisition, HSV2 can cause ulcers and
microulcerations, and GUD has been associated with a 7–11-
fold risk of HIV acquisition in cohort studies.51–53 In a meta-
analysis of the epidemiological literature of HSV2 and the risk
of HIV infection, cohort and nested case–control studies
showed an increased risk of acquiring HIV in HSV2-seropositive
heterosexual men (risk ratio (RR) 2.7, 95% confidence interval
(CI) 1.9 to 3.9), men who have sex with men (RR 1.7, 95% CI
1.2 to 2.4), and women from the general population (RR 3.1,
95% CI 1.7 to 5.6). Among high-risk women, RR values ranged
widely, and the summary estimate did not show a significant
association (RR 1.0, 95% CI 0.5 to 2.0).38 HIV acquisition risk is
highest among those with recent HSV2 infection,39–42 which
may reflect the higher frequency and severity of herpetic ulcers
during the early stages of HSV2.
HSV2 infection may enhance HIV and HSV2 transmission
among people with coinfection. HIV RNA has been isolated from
herpetic lesions, and clinically recurrent herpes and asympto-
matic shedding is associated with transient increases in HIV load
in plasma and genital secretions.44–46 These findings suggest that
HSV2 reactivation may increase HIV infectiousness. Gray et al30
studied HIV transmission rates per sex act among HIV-discordant
monogamous couples in Rakai, Uganda. The two most important
risk factors for HIV transmission were the presence of genital
ulcers and higher HIV plasma load.30 Most GUDs in Rakai (87% of
all ulcers with known aetiology) were due to HSV2.
Genital herpes in people with HIV infection
Although clinical observations suggest that patients with HIV
have more frequent and prolonged episodes,54 few studies have
examined the effect of HIV on the natural history of HSV2
infection. The influence of immunodeficiency on the clinical
expression of HSV2 infection is complex, and although impaired T
cell function is expected to increase HSV2 re-activation rates and
shedding, it may also reduce the host imflammatory response, and
therefore the clinical expression of HSV2 infection. Consistent
with this hypothesis, HSV2 infection has been included as a
possible manifestation of the immunoreconstitution syndrome
induced by highly active antiretroviral therapy.55 Available data
from cohort studies among people with dual infections do not
show more symptomatic herpes manifestations among HIV-
positive people but do show increased HSV2 shedding. Schacker et
al47 showed that HIV status had only a modest effect on the rate
and duration of clinical recurrences (0.34 v 0.23 recurrences per
month among HIV-negative people); however, the rate of
subclinical shedding was markedly higher among HIV-positive
people. Ramaswamy et al56 followed up 549 HIV/HSV2-infected
people and reported that only 21% had a clinical diagnosis of
genital herpes over a median 5 years of follow-up.
LABORATORY DIAGNOSIS OF GENITAL HERPES:
OPTIONS FOR RESOURCE-LIMITED SETTINGS
Virus detection in genital swabs
Virus isolation in cell culture has long been considered the
diagnostic gold standard for HSV. Specificity is virtually 100%,
but levels of virus shedding, specimen quality and transport
conditions influence sensitivity. Test performance declines with
time since the onset of lesions and is on average 52–93% for
vesicles, 41–72% for ulcers and 19–27% for crusted lesions.57 PCR
increases the sensitivity of culture by 11–75%,58 and it has recently
been recommended as the new diagnostic gold standard for
genital herpes.59 Additional methods include detection of viral
antigen by direct immunofluorescence assay using fluorescein-
labelled monoclonal antibodies on smears, or by enzyme
immunoassay on swabs. Immunofluorescence is expensive and
shows lower sensitivity (74%) and specificity (85%) than virus
culture.60 Antigen enzyme immunoassay shows >95% specificity
and 62–100% sensitivity relative to virus culture.61
HSV2-specific serology
Commercially available assays to detect antibodies to HSV2-
specific glycoprotein gG-2 have markedly improved serological
diagnosis of HSV2 infection over the past 10 years. These tests
have been evaluated in industrialised countries, and their
sensitivity against western blot ranged from 93% to 100%, and
the specificity ranged from 95% to 100%.59 Recent evaluations of
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Figure 1 Prevalence of herpes simplex virus type 2 (HSV2) among sex
workers, women not at high risk, and men from Africa, Latin America and
Asia. SW, sex worker, LA, Latin America. Data abstracted from tables 1–3
from Weiss.6 Studies providing only pooled estimates for women and men
were not included; for sex workers in Africa, Latin America and Asia, only
two studies were available per continent; seven studies were included for
women not at high risk in Africa; eleven for women in Latin America, seven
for women in Asia; six for men in Africa; three for men in Asia, and no
studies were available for men in Latin America.
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Table 1 Review of aetiology of genital ulcer disease in Africa, Asia and Latin America
City, country,
reference Year Population
Aetiology of genital ulcer disease, n (%) Serology, n (%)
Laboratory techniquesTP HD HSV LGV
Mixed
aetiology
No
detection HSV2 Syphilis HIV
Africa
Gaborone,
Botswana7
1993 108 M, F 1 (1) 27 (25) 25 (23) 2 (2) 5 (5) 58 (54) NR 56 (52) 40 (37) TP dark field; HD, CT and HSV
culture; syphilis serology
RPR+TPHA; CT antibodies MIF;
HIV ELISA
Gaborone,
Francistown and
Selebi Phikwe,
Botswana7
2002 137 M, F 2 (2) 1 (1) 80 (58) NR 0 (0) 54 (39) NR 7 (5) 72 (74) TP, HD and HSV MPCR; syphilis
serology RPR+TPHA; HIV ELISA
Nairobi,
Kenya8
1985 89 F 11 (12) 43 (48) 2 (2) NR 3 (3) 31 (35) NR 24 (27) NR TP dark field; HD and HSV culture;
syphilis serology RPR+MHA-TP
Nairobi,
Kenya9
1985 115 M 3 (3) 81 (70) 10 (9) NR NR 21 (18) 37 (32) 17 (15) 19 (17) TP dark field; HD and HSV culture;
syphilis serology RPR+FTA-abs;
HSV2 serology western blot; HIV
ELISA+western blot
Nairobi,
Kenya10
1990–1 168 M, F NR 56 (33) NR NR NR NR NR 24 (14) NR HD culture; syphilis serology
RPR+TPPA
Nairobi,
Kenya11
1995–7 245 M, F 89 (36) 111 (45) 49 (20) NR 39 (16) 36 (15) NR 69 (28) 88 (36) TP, HD and HSV MPCR; syphilis
serology RPR+TPHA; HIV EIA
Maseru,
Lesotho12
1993–4 105 M, F 23 (23) 56 (56) 26 (26) 7 (7) 17 (17) 6 (6) 54 (54) 25 (25) 37 (36) TP, HD and HSV MPCR; syphilis
serology RPR+FTA-abs; CT
antibodies MIF; HIV
ELISA+western blot; HSV2
serology western blot
Blantyre,
Malawi13
1993 778 M 136 (20) 204 (26) NR NR NR NR NR 129 (17) 445 (57) TP direct IF; HD culture; syphilis
serology RPR+MHA-TP; HIV ELISA
Lilongwe,
Malawi14
1998–9 137 M, F 5 (4) 41 (30) 47 (34) NR 2 (1) 46 (34) 107 (80)12 (9) NR TP, HD and HSV MPCR; syphilis
serology RPR+TPPA; HSV2 serology
focus
Antananarivo,
Madagascar15
1997 196 M, F 56 (29) 64 (33) 19 (10) NR 6 (3.1) 62 (32) NR 59 (33) NR P, HD and HSV MPCR; syphilis
serology RPR+
TPHA; CT antibodies MIF
Kigali,
Rwanda16
1986 210 M, F 63 (30) 36 (34) 37 (18) 29 (14) 29 (14) 75 (36) NR 81 (39) 124 (59) HD, LGV and HSV culture;
primary syphilis defined as
RPR.1:2 and TPHA or FTA-abs
positive; syphilis serology
RPR+TPHA or FTA-abs; HIV ELISA
Kigali,
Rwanda17
1990–2 395 M, F 110 (28) 115 (29) 89 (23) NR 46 (12) 127 (32) NR NR 289 (73) HD, LGV and HSV culture;
primary syphilis defined as
RPR.1:2 and TPHA or FTA-abs
positive; syphilis serology
RPR+TPHA or FTA-abs; HIV ELISA
Dakar, Senegal18 1992 39 M, F 6 (15) 22 (56) 5 (13) NR 4 (10) 10 (26) NR NR NR TP, HD, HSV PCR
Carletonville,
South Africa19*
NR, 1990
publication
date
240 M 25 (10) 147 (61) 7 (3) 15 (6) 14 (6) 29 (12) NR 52 (47) NR TP dark field; HD, CT and HSV
culture; syphilis serology
RPR+FTA-abs; CT antibodies MIF;
donovanosis Giemsa stain
Carletonville,
South Africa20
1993–4 232 M 24 (10) 161 (69) 40 (17) NR 17 (7) 25 (11) NR 110 (48) 126 (54) TP, HD and HSV MPCR; syphilis
serology RPR+FTA-abs; HIV ELISA
Carletonville,
South Africa20
1998 186 M 23 (12) 94 (51) 67 (36) NR 31 (17) 39 (21) NR 74 (40) 108 (59) TP, HD and HSV MPCR; syphilis
serology RPR+FTA-abs; HIV ELISA
Cape Town,
South Africa21
1993–4 180 M 59 (33) 31 (17) 43 (24) NR 6 (3) 54 (30) 86 (49) 61 (47) 24 (13) TP, HD and HSV MPCR; syphilis
serology RPR+FTA-abs; HSV2
serology western blot; HIV
ELISA+western blot
Johannesburg,
South Africa21
1993–4 159 M 19 (10) 34 (21) 78 (49) NR 6 (4) 34 (21) 78 (50) 58 (46) 76 (48) TP, HD and HSV MPCR; syphilis
serology RPR+FTA-abs; HSV2
serology western blot; HIV
ELISA+western blot
Durban, South
Africa22
1984 100 M 23 (23) 40 (40) 9 (9) NR 11 (11) 41 (41) 97 (97) 35 (35) NR TP dark field; culture HD and HSV;
HSV2 serology ELISA; syphilis
serology RPR+FTA-abs
Durban, South
Africa23*
1988–9 100 M 42 (42) 34 (34) 10 (10) 6 (6) 14 (14) 24 (24) NR 44 (44) 5 (5) TP dark field; culture HD and HSV;
syphilis serology RPR+TPHA; CT
antibodies MIF; HIV ELISA;
donovanosis Giemsa stain
Durban, South
Africa24*
1988–9 100 F 40 (40) 14 (14) 18 (18) 6 (6) 13 (13) 20 (20) NR 49 (49) 3 (3) TP dark field; culture HD and HSV;
syphilis serology RPR+TPHA; CT
antibodies MIF; HIV ELISA;
donovanosis Giemsa stain
Durban, South
Africa21
1993–4 199 M 29 (15) 106 (53) 72 (36) NR 33 (17) 29 (15) 81 (49) 39 (23) 115 (58) TP, HD, HSV MPCR; syphilis
serology RPR+FTA-abs; HIV
ELISA+western blot
Durban, South
Africa25*
2000–1 587 M, F 85 (14) 57 (10) 284
(48)
63 (11) 63 (11) 156 (27) NR NR 441 (75) TP, HD, HSV MPCR; LGV PCR;
primary syphilis PCR+ or FTA-
abs+EIA or FTA-abs+RPR; HIV
Determine+Capillus
Dar es Salaam
and Mbeya,
Tanzania26
1999 102 M, F 1 (1) 21 (21) 59 (58) NR 9 (9) 39 (38) NR 15 (15) 50 (48) TP, HD, HSV MPCR, syphilis
serology RPR+TPPA, HIV
Determine+ELISA
18 Paz-Bailey, Ramaswamy, Hawkes, et al
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these tests have raised concerns about lower specificity with
African sera.62–64 These findings could be due to problems of cross-
reactivity, or reflect the fact that some tests detect HSV2
seroconversions earlier than others, including western blot. It
has been recommended that the threshold for calculating positive
results should be increased as a way of improving specificity,
although this may also reduce sensitivity in early infection.63
The role of routine laboratory investigations
The cost:benefit ratio of adopting virus detection and HSV2-
specific serology for routine management of patients attending
STI clinics in developing countries remains currently uncertain.
Given that the clinical diagnosis of genital herpes is typically
unreliable, a laboratory confirmation is desirable. Antigen
enzyme immunoassay may be an option for resource-limited
settings, as assays are commercially available and easy to
perform, but the test is expensive and its sensitivity is suboptimal.
Although PCR allows less stringent conditions for sample storage
and transport than virus culture and can be highly automated, it
requires sophisticated laboratory equipment, high-level technical
expertise and strict quality control. These conditions combined
make PCR a difficult diagnostic option in most resource-limited
settings. Centralised laboratory facilities may be one method of
providing testing. Although results may not be available for
immediate patient management, important information is gained
on local epidemiology of GUD and the validity of syndromic
approaches to GUD management, thus assisting programme
managers in evidence-based decision making.
Similar considerations apply to the use of HSV-specific
serology for screening purposes, given that the tests are
expensive and in many settings infection with HSV2 is nearly
universal among patients with GUD. The strongest argument in
favour of screening is that HSV2-seropositive people can be
counselled about the increased risk of HIV acquisition.64 Thus,
the scope for using HSV2 serology to detect infected people may
grow in developing countries should evidence from ongoing
studies support the use of antiviral treatment against HSV2 as a
strategy for HIV prevention. In this case, serological screening
could be considered to identify people coinfected with both
viruses who could benefit from suppressive anti-HSV2 treat-
ment. This might be especially important for couples with
discordant HSV2/HIV serostatus.
CURRENT TREATMENT STRATEGIES
Antiviral treatment
For bacterial STI, treatment is usually short and aimed at both
reducing the duration and severity of symptoms and eliminating
theaetiological agent. For viral STI such as herpes, treatment can be
either short and episodic, which will reduce the severity and
duration of symptomatic recurrences, or longer-term supressive
treatment, which will reduce both the number and severity of
symptomatic episodes and asymptomatic shedding. Episodic
treatment in recurrent episodes reduces pain, decreases time to
ulcer healing by 1–2 days and reduces HSV2 shedding by 1–2 days,
although it has no effect on recurrence rates.65 66 Suppressive
treatment with aciclovir can prevent or delay 80% of recurrences,
and reduce clinical and subclinical shedding by.90%.67 Aciclovir’s
pharmaceutical patent has recently expired and the drug is now
available in generic form from nine manufacturers in seven
countries worldwide for,US$0.20 per tablet.68
City, country,
reference Year Population
Aetiology of genital ulcer disease, n (%) Serology, n (%)
Laboratory techniquesTP HD HSV LGV
Mixed
aetiology
No
detection HSV2 Syphilis HIV
Dar es Salaam,
Tanzania27
NR 69 M, F NR NR 45 (64) NR NR n 55 (80) NR 29 (42) TP, HD and HSV MPCR; HSV2
serology ELISA; HIV ELISA
Fajara, The
Gambia28
1980 104 M, F 5 (5) 54 (52) 4 (4) 7 (7) NR 28 (27) NR 22 (21) NR TP dark field TP; HD, CT and HSV
culture; syphilis VDRL+TPHA; CT
serology MIF
Kampala,
Uganda29
1990–1 98 M, F 2 (2) 0 (0) 35 (36) 0 (0) 2 (2) 61 (61) NR 11 (12) 58 (65) TP dark field; HSV
immunofluorescence; HIV EIA;
syphilis RPR+MHA-TP; CT serology
MIF
Rakai,
Uganda30
1994–8 207 M, F 8 (4) 6 (3) 89 (43) NR NR 103 (51) NR NR 0 TP, HD, HSV MPCR; syphilis
serology TRUST+TPHA; HIV
ELISA+western blot
Asia
Pune, India31 1994 302 M, F 29 (10) 69 (23) 79 (26) NR 21 (7) 104 (34) NR NR 67 (22) TP, HD, HSV MPCR; syphilis
serology VDRL+FTA-abs; HIV
ELISA+western blot
Kuala Lumpur,
Malaysia32
1989–90 249 M, F 18 (7) 22 (9) 48 (19) 4 (2) 3 (1) 153 (62) NR 41 (17) NR TP dark field TP; HD, CT and HSV
culture; syphilis serology
RPR+TPHA
Chiang Mai,
Thailand33
1995–6 38 M, F 1 (3) 0 (0) 32 (84) NR 1 6 (16) NR NR 11 (46) TP, HD, HSV MPCR; HIV test NR
Latin America
Santo Domingo,
Dominican
Republic34
1995–6 81 M 4 (5) 21 (26) 35 (43) NR 0 21 (26) NR 6 (7) 11 (14) TP, HD, HSV MPCR; syphilis
serology VDRL+FTA-abs; HIV
ELISA+western blot
Kingston,
Jamaica35
1996 304 M, F 31 (10) 72 (24) 158 (52)NR 22 (7) 67 (22) NR 64 (21) 67 (22) TP, HD, HSV MPCR; syphilis
serology TRUST+MHA-TP; HIV
ELISA+western blot
Lima, Peru34 1994–5 63 M 6 (10) 3 (5) 27 (43) NR 3 (5) 30 (48) NR 5 (8) 2 (3) TP, HD, HSV MPCR; syphilis
serology RPR+MHA-TP; HIV
ELISA+western blot
CT, Chlamydia trachomatis; EIA, enzyme immunoassay; F, female; FTA-abs, fluorescent treponemal antibody absorption; HD, Haemophilus ducreyi; HSV, herpes simplex virus; IF,
immunofluorescence; LGV, Lymphogranuloma venereum; M, male; MHA-TP, microhaemagglutination assay for Treponema pallidum; MIF, microimmunofluorescence; MPCR,
multiplex polymerase chain reaction; NR, not reported; PCR, polymerase chain reaction; RPR, rapid plasma reagin; TP, Treponema pallidum; TPHA, Treponema pallidum
haemagglutination assay; TPPA, Treponema pallidum particle agglutination assay; TRUST, toluidine red unheated serum test; VDRL, venereal disease research laboratory.
*Donovanosis reported only in three studies from South Africa: 1 (0.4%) case from Carletonville in 1990,15 11 (11%) among women and 16 (16%) among men in 1989 in Durban19 20
and 8 (1%) in 2001 in Durban.21
Number of cases and percentage for each organism include cases of mixed etiology; therefore percentages will not add up to 100%.
Table 1 Continued
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Addition of aciclovir to the syndromic management of GUD
Previous WHO guidelines for the treatment of GUD were
concerned with bacterial aetiologies and provided no sugges-
tions for effective treatment for genital herpes. Owing to the
observed increases in the worldwide prevalence of HSV2
infection, the WHO now recommends giving antiherpes
treatment in places where the relative prevalence of HSV2
infection is .30%.3 Botswana is the first country in Africa to
incorporate aciclovir treatment for GUD management, and the
government is closely monitoring its implementation.7
However, some questions about the incorporation of antiherpes
treatment into syndromic management still remain. Firstly,
evidence on the effect of episodic aciclovir treatment on ulcer
duration suggests that it is primarily effective when given early,
ideally at ulcer onset. Under field conditions, patients attending
primary healthcare facilities are likely to have a delay in
symptom recognition, and thus there is a delay in initiating
treatment. Treatment strategies will have to be accompanied by
successful campaigns targeting early symptom recognition and
prompt treatment. Secondly, unnecessary overtreatment might
become more common, as syphilis and chancroid are becoming
rare, and herpes is responsible for most cases of GUD.
Treatment for these bacterial infections will probably have to
continue for several years until syphilis and chancroid are
eliminated. The WHO is currently assembling a 5-year control
initiative for genital ulcers, with the goal of eliminating
chancroid and reducing the prevalence of syphilis.69 Thirdly, it
is still unclear how partner notification for herpes contacts will
be implemented. Although many patients are infected by
asymptomatic partners, some may be taught to recognise signs
and symptoms of genital herpes that were previously unrecog-
nised. Counselling would provide an opportunity for health
education, condom promotion, HIV testing and reinforcing
abstention from sexual intercourse while lesions are present.70
Finally, further adjustment to algorithms for GUD management
will be needed in areas with a high prevalence of HIV where
delayed healing of ulcers and multiple recurrences are already
an increasing problem. These patients would greatly benefit
from suppressive treatment.
Trials are currently under way in South Africa, Ghana and
Malawi to evaluate the incorporation of aciclovir into the
syndromic management of GUD and its effect on reduction of
pain, ulcer healing and HIV shedding from ulcers (table 2). The
cost effectiveness of this strategy needs to be determined.
Treatment of genital herpes for the prevention of
acquisition and transmission of HIV
As antiviral treatment can reduce virus shedding and viral
loads, it has been hypothesised that they also reduce transmis-
sion of HSV2 and HIV infections. The first trial to assess the
effect of antiviral treatment on the heterosexual transmission
of a viral infection has been completed recently. Provision of
suppressive treatment was shown to reduce HSV2 transmis-
sion. A multicentre study among monogamous, heterosexual,
HSV2-discordant couples found that a once-daily suppressive
dose of valaciclovir reduced the incidence of symptomatic
genital herpes among the uninfected by 77% and the overall
risk of transmission by 50%.71
Several trials are under way to evaluate the effect of antiherpes
treatment in reducing HIV transmission and acquisition. These
trials are considering the following public health issues:
1. Reducing the enhancing effect of HSV2 on HIV, by episodic
treatment of genital herpes in populations with high risk of
transmission or acquisition of HIV (ie patients with STI)
2. Supression of HSV2, to reduce susceptibility to HIV among
HIV-negative, HSV2-seropositive people
3. Suppression of HSV2, to reduce infectiousness of HIV
among people with HIV/HSV2 coinfection.64
Encouraging data were recently presented by Nagot et al72
showing that suppressive treatment with valaciclovir reduced
Table 2 Research Initiatives Evaluating HSV-2 and HIV-1 Interactions and the Use of Anti-Herpes Therapy to Reduce Acquisition
and Transmission of HIV-1
Intervention Population Outcome Status
HSV-2 suppressive treatment
Acyclovir treatment to
prevent HIV-1 acquisition
1600 HIV-1-negative HSV-2-positive women, in
Zimbabwe, Zambia and Johannesburg; and,
1600 high-risk, HIV-1-negative HSV-2-positive men
who have sex with men in Peru and United States
HIV-1 incidence Ongoing until the end of 2006
Acyclovir treatment to
prevent HIV-1 acquisition
and reduce HIV-1 vaginal
shedding
1300 HSV-2-positive high risk women, both
HIV-1-positive and negative in Tanzania
HIV-1 incidence among initially HIV-, and
HSV-2 & HIV-1 vaginal shedding among
HIV-1-positive
Ongoing until 2007
Acyclovir treatment to
prevent HIV-1
transmission
3646 HIV-1 discordant couples (HIV-1-positive
partner is also HSV-2-positive and has a CD4 count
of 250 cells/mm3) in Botswana, Kenya, Zambia,
Rwanda, Tanzania and Uganda
HIV-1 incidence in HIV-1-negative partner Ongoing until 2007
Valacyclovir treatment to
reduce HIV-1 shedding
140 HIV-1-positive HSV-2-positive women in
Burkina Faso
HIV-1 cervico-vaginal and plasma viral
loads
Finished recruitment October
2005
Acyclovir treatment to
reduce HIV-1 shedding
300 HIV-1-positive HSV-2-positive women in
South Africa
HIV-1 and HSV-2 cervico-vaginal and
plasma viral loads
Finished recruitment in May 2006
Acyclovir treatment to
reduce HIV-1 shedding
67 HIV-1 and HSV-2 infected women, Chiang Rai,
Thailand
HIV-1 and HSV-2 cervico-vaginal shedding Finished recruitment in 2006
Acyclovir treatment to
reduce HIV-1 shedding
380 HIV-1/HSV-2 positive high-risk women in
Tanzania (part of the second study listed above)
HIV-1 and HSV-2 cervico-vaginal and
plasma viral loads
Finished follow-up in October
2005
HSV-2 episodic treatment as part of syndromic management of genital ulcer disease
Acyclovir treatment for
5 days
600 men HIV-1-positive and negative with genital
ulcers in South Africa
Ulcer healing, HIV-1 ulcer shedding Ongoing until the end of 2006
Acyclovir treatment for
5 days
410 women HIV-1 positive and negative with genital
ulcers in Ghana and Central African Republic
Ulcer healing, HIV-1 cervico-vaginal and
ulcer shedding
Finished recruitment in October
2005
Acyclovir treatment for
5 days
400 men and women HIV-1 positive and negative
with genital ulcers in Malawi
Ulcer healing, HIV-1 vaginal, ulcer and
semen shedding
Ongoing until July 2006
20 Paz-Bailey, Ramaswamy, Hawkes, et al
www.stijournal.com
HIV vaginal shedding and HIV plasma load among women with
dual infections.
OTHER HERPES INTERVENTIONS
Condom use
Few studies have evaluated the protection provided by condoms
against genital herpes. Most cross-sectional studies have failed to
show an association and even suggest increased risk among men
using condoms,73 probably because condom use is a marker of
high-risk relationships. One prospective study reported protection
from condom use only among women.74 A more recent study
showed that participants reporting more frequent condom use
(condom use for .75% of sexual acts) were at a lower risk of
acquiring HSV2 (hazard ratio 0.7, 95% CI 0.6 to 0.9).75
HSV2 vaccines
Although animal studies on vaccination strategies to prevent
genital and neonatal herpes may be promising, clinical trials of
HSV2 vaccines in humans have failed to prove efficacy.1 In a
recent study, an HSV2 glycoprotein D vaccine using alum
morpholine as adjuvant induced protection from clinical disease
(73%) and overall HSV2 transmission (about 40%).76 By contrast,
no protective efficacy was observed with a similar vaccine based
on the viral glycoproteins B and D and using MF59 as adjuvant.77
The protective effect of the MPL vaccine was seen only in women
who were HSV1 and HSV2 seronegative, and there was no
protection among men or among HSV1-seropositive women.76 The
partial efficacy was shown to be related to the induction of T cell
immunity with a T helper 1 profile. The vaccine is currently being
evaluated in a large multicentre trial targeting pre-pubertal girls.
DISCUSSION
HSV2 is highly prevalent in most regions, especially those
experiencing HIV epidemics, and it has become the most
important cause of GUD worldwide. In addition to the suffering
and expense incurred by people with HSV2 infections,
substantial data support an important role of HSV2 in
facilitating HIV transmission and acquisition.
As with all STIs, the most cost-effective intervention is primary
prevention. However, STI control has been successful only in a
limited number of settings, and primary prevention programmes
have obstacles of acceptance and effectiveness among popula-
tions who are both vulnerable and at risk. Given the epidemiology
of HSV2 acquisition as primarily an incident infection among
young people, we should undoubtedly be focusing primary
prevention efforts on this age group, especially in resource-poor
settings where incidence and prevalence remain highest. Primary
prevention should include delaying sexual debut among adoles-
cents and reducing the number of sexual partners. Male condoms
protect against HSV2 less effectively than against HIV, but still
have some efficacy.74 Given the strong efficacy of condoms in
protecting against HIV and other STIs, promotion of condom use
should always be included in any STI prevention effort.
Once infected with HSV2, a lifelong viral infection requires
different management strategies compared with managing ‘‘one-
off’’ bacterial infections. Although conventional wisdom may
have mitigated against the cost effectiveness of trying to control a
recurrent infection in resource-poor settings, increasing evidence
of the interaction between HSV2 infection and the risk of HIV
transmission, and the increasing contribution of HSV2 to the
burden of GUD, has raised the salience of HSV2. Whether
providing suppressive or episodic antiviral treatment, more
attention should be focused on ensuring that people infected
with HSV2 have access to appropriate and effective care. Services
should be part of a prevention package including HIV testing and
counselling to all patients with STI, counselling to improve
recognition of herpes symptoms, early initiation of episodic
aciclovir treatment and counselling on condom use, and
abstaining from sexual intercourse during herpes outbreaks.
Prevention and treatment strategies should be first targeted at
people with genital herpes lesions. Although these may be a small
proportion of those who are HSV2 seropositive, people with lesions
are at highest risk of transmitting the virus. Questions on the effect
of antiherpes treatment in preventing HIV transmission and
acquisition remain unanswered. Ongoing trials will assist in filling
these knowledge gaps and will provide the evidence required to
design new interventions for herpes. In countries in sub-Saharan
Africa, where the prevalence of HSV2 is extremely high, the
provision of aciclovir for people with genital ulcers who are being
treated syndromically might represent the most cost-effective and
easiest means to implement a strategy for HIV prevention.
While the inclusion of herpes treatment in syndromic manage-
ment is further evaluated on the basis of current WHO and US STI
management recommendations,2 72 aciclovir should be made
available for patients with primary herpes (although hard to
identify in developing countries), those with severe episodes,
immunosuppressed patients and patients with frequent recur-
rences. Developing countries should also consider adding aciclovir
to the essential drug list. Further, with the help of WHO, aciclovir
should be made available and affordable in developing countries.
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